Journal Watch · Clinical Cancer Research · 2026
Proteogenomic profiling identifies FGFR2b as a prevalent cell-surface target in intrahepatic cholangiocarcinoma.
Orthogonal validation using immunohistochemistry in a subset of 20 patients with available tissue samples confirmed membrane-bound FGFR2b expression in 31.6% of iCCA cases, including all patients with FGFR2 fusions.<h4>Conclusions</h4>Our findings identify FGFR2b as a prevalent and compelling therapeutic target in iCCA and provide strong rationale for ongoing and future FGFR2b-targeted clinical trials.
TL;DR
Orthogonal validation using immunohistochemistry in a subset of 20 patients with available tissue samples confirmed membrane-bound FGFR2b expression in 31.6% of iCCA cases, including all patients with FGFR2 fusions.<h4>Conclusions</h4>Our findings identify FGFR2b as a prevalent and compelling therapeutic target in iCCA and provide strong rationale for ongoing and future FGFR2b-targeted clinical trials.
Key findings
- High FGFR2b expression was associated with improved surgical outcomes, epithelial differentiation, and reduced CD8+ T-cell infiltration.
- Orthogonal validation using immunohistochemistry in a subset of 20 patients with available tissue samples confirmed membrane-bound FGFR2b expression in 31.6% of iCCA cases, including all patients with FGFR2 fusions.<h4>Conclusions</h4>Our findings identify FGFR2b as a prevalent and compelling therapeutic target in iCCA and provide strong rationale for ongoing and future FGFR2b-targeted clinical trials.
Numbers at a glance (from the abstract)
Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.
What they did
In particular, gene-level analyses overlook tumor-enriched protein isoforms produced through alternative splicing.<h4>Experimental design</h4>To address this gap, we applied a novel isoform-resolved proteogenomic approach comprising transcriptomics, in silico translation, and cell surfaceomics to identify prevalent cell surface targets in iCCA, and further assessed their specificity through analysis of expression data from the TCGA and GTEx datasets.<h4>Results</h4>This approach identified a unique peptide corresponding to FGFR2b, a splicing isoform of FGFR2, that demonstrated markedly higher tumor enrichment than the alternative FGFR2 isoform, FGFR2c. FGFR2b was the predominant FGFR2 isoform in BTC, including iCCA, in both our institutional cohort (88.6%) and TCGA (88.2%). FGFR2 fusions, in particular, were associated with high FGFR2b expression.
Full abstract (original)
Background: <h4>Purpose</h4>Intrahepatic cholangiocarcinoma (iCCA) is rising in incidence and is associated with limited treatment options and poor prognosis, particularly in advanced disease. Recently, biologic strategies such as antibody-drug conjugates (ADCs) have expanded therapeutic opportunities across many tumor types, including HER2/neu-altered iCCA. However, validated and prevalent cell surface targets suitable for biologic therapies remain uncommon in iCCA, representing a critical bottleneck to the development of novel targeted treatments.
What they did: In particular, gene-level analyses overlook tumor-enriched protein isoforms produced through alternative splicing.<h4>Experimental design</h4>To address this gap, we applied a novel isoform-resolved proteogenomic approach comprising transcriptomics, in silico translation, and cell surfaceomics to identify prevalent cell surface targets in iCCA, and further assessed their specificity through analysis of expression data from the TCGA and GTEx datasets.<h4>Results</h4>This approach identified a unique peptide corresponding to FGFR2b, a splicing isoform of FGFR2, that demonstrated markedly higher tumor enrichment than the alternative FGFR2 isoform, FGFR2c. FGFR2b was the predominant FGFR2 isoform in BTC, including iCCA, in both our institutional cohort (88.6%) and TCGA (88.2%). FGFR2 fusions, in particular, were associated with high FGFR2b expression.
Results & conclusions: High FGFR2b expression was associated with improved surgical outcomes, epithelial differentiation, and reduced CD8+ T-cell infiltration. Orthogonal validation using immunohistochemistry in a subset of 20 patients with available tissue samples confirmed membrane-bound FGFR2b expression in 31.6% of iCCA cases, including all patients with FGFR2 fusions.<h4>Conclusions</h4>Our findings identify FGFR2b as a prevalent and compelling therapeutic target in iCCA and provide strong rationale for ongoing and future FGFR2b-targeted clinical trials.
Abstract © the authors / Clinical Cancer Research (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1158/1078-0432.ccr-25-4993 · PubMed 42611968.
Why it matters for pharma & biotech
- Directly relevant to teams in antibody / ADC therapeutics, targeted oncology / immuno-oncology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: antibody / ADC therapeutics · targeted oncology / immuno-oncology
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
Frequently asked questions
What did this Clinical Cancer Research study find?
Orthogonal validation using immunohistochemistry in a subset of 20 patients with available tissue samples confirmed membrane-bound FGFR2b expression in 31.6% of iCCA cases, including all patients with FGFR2 fusions.<h4>Conclusions</h4>Our findings identify FGFR2b as a prevalent and compelling therapeutic target in iCCA and provide strong rationale for ongoing and future FGFR2b-targeted clinical trials.
What type of study is this?
It is a cohort / observational clinical study, published in Clinical Cancer Research in 2026. In particular, gene-level analyses overlook tumor-enriched protein isoforms produced through alternative splicing.<h4>Experimental design</h4>To address this gap, we applied a novel isoform-resolved proteogenomic approach comprising transcriptomics, in silico translation, and cell surfaceomics to identify prevalent cell surface targets in iCCA, and further assessed their specificity through analysis of expression data from the TCGA and GTEx datasets.<h4>Results</h4>This approach identified a unique peptide corresponding to FGFR2b, a splicing isoform of FGFR2, that demonstrated markedly higher tumor enrichment than the alternative FGFR2 isoform, FGFR2c.
Where can I read the original paper?
The original is at the publisher via DOI 10.1158/1078-0432.ccr-25-4993. PubMed ID: 42611968. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/proteogenomic-profiling-identifies-fgfr2b-as-a-prevalent-cell-surface-ta-254993/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides